Clinical Trials

Sponsor: BioAtla, LLC

Sponsor Study ID: BA3021-001

Study Title: A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination With Nivolumab In Patients With Advanced Solid Tumors

NCT Number: NCT03504488

Phase: I/II

Protocol Type: Treatment

Age Group: Adult

Disease Sites: Lung

Study Objectives: The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors

For more information about the trial above please contact the study team:

Principal Investigator, Mariam Alexander, at alexanma@musc.edu.
Study Coordinator, Megan Buss, at bussm@musc.edu.

Trial opened at the following institutions: Medical University of South Carolina

Study Documents
(MUSC NetID required for document access)